^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PPAR γ agonist

    Related drugs:
    1d
    Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis (clinicaltrials.gov)
    P3, N=102, Active, not recruiting, Zydus Therapeutics Inc. | Recruiting --> Active, not recruiting | N=150 --> 102
    Enrollment closed • Enrollment change
    2d
    Chiglitazar Added to SGLT-2 Inhibitors for Type 2 Diabetes (clinicaltrials.gov)
    P=N/A, N=3550, Not yet recruiting, Chipscreen Biosciences, Ltd.
    New trial
    2d
    EPICS-IV: Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy (clinicaltrials.gov)
    P3, N=89, Not yet recruiting, Zydus Therapeutics Inc. | Initiation date: Mar 2026 --> Jun 2026
    Trial initiation date
    14d
    Evaluation of Chiglitazar Sodium With Lifestyle Intervention for Reversing Prediabetes (clinicaltrials.gov)
    P=N/A, N=472, Not yet recruiting, Second Xiangya Hospital of Central South University
    New trial
    16d
    ENRICHPLUS: Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone (clinicaltrials.gov)
    P2, N=1, Terminated, University of Maryland, Baltimore | Trial completion date: Sep 2024 --> Dec 2025
    Trial completion date
    18d
    MT-1-02: A PHASE?1, OPENLABEL, SINGLECENTER STUDY TO EVALUATE DRUGDRUG INTERACTIONS WITH GEMFIBROZIL, ITRACONAZOLE, AND CARBAMAZEPINE AND THE FOOD-EFFECT ON ORAL LERIGLITAZONE IN MALE HEALTHY SUBJECTS (2025-521508-23-00)
    P1, N=73, Active, not recruiting, Minoryx Therapeutics S.L. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    itraconazole
    21d
    Sex Differences in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Epidemiology, Pathophysiology, and Clinical Implications. (PubMed, J Clin Exp Hepatol)
    Evidence suggests differential treatment responses, with pioglitazone showing greater efficacy in women with prediabetes/type 2 diabetes...Sex and gender differences in MASLD are evident globally. Integrating sex and reproductive status into MASLD management is essential for advancing personalized medicine worldwide.
    Review • Journal
    |
    PNPLA3 (Patatin Like Phospholipase Domain Containing 3)
    23d
    Co-treatment of Colchicine and Rosiglitazone synergistically inhibits cytokine-driven inflammation and modulates the related hsa-miRNA26a-5p, hsa-miRNA21-5p, and STAT3 expression in non-small cell lung cancer. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    The findings highlight the need for further investigation into the Col/Rosi combination for inflammation-related lung cancer and p53 expression. In vitro studies and bioinformatics analyses suggest a miRNA-associated regulatory mechanism that could guide future research.
    Journal • PARP Biomarker
    |
    PTEN (Phosphatase and tensin homolog) • IL6 (Interleukin 6) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • MIR21 (MicroRNA 21) • CASP3 (Caspase 3) • LIN28B (Lin-28 Homolog B)
    |
    TP53 mutation • TP53 wild-type
    |
    rosiglitazone
    27d
    Insights from changes in NDEV biomarkers of metabolism: Effects of PPARγ and GLP1 receptor agonists on brain metabolism. (PubMed, J Clin Endocrinol Metab)
    Our findings demonstrate CNS-specific biomarker responses to both PPARγ agonists and GLP1 receptor agonists.
    Journal
    |
    PPARG (Peroxisome Proliferator Activated Receptor Gamma) • RPS6 (Ribosomal Protein S6)
    29d
    CT-L03-301: Clinical study to evaluate the efficacy and safety of Pioglitazone co-administration in patients with type II diabetes with insufficient glycemic control with Metformin and Empagliflozin combination therapy (2023-508924-36-00)
    P2/3, N=224, Completed, Celltrion Inc. | Active, not recruiting --> Completed
    Trial completion
    1m
    Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets (clinicaltrials.gov)
    P=N/A, N=64, Not yet recruiting, Chipscreen Biosciences, Ltd.
    New trial
    1m
    Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets (clinicaltrials.gov)
    P1, N=28, Not yet recruiting, Chipscreen Biosciences, Ltd.
    New P1 trial